{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:52:38Z","timestamp":1792500758269,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["DP2 TR002776"],"award-info":[{"award-number":["DP2 TR002776"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["DP2 TR002776"],"award-info":[{"award-number":["DP2 TR002776"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["DP2 TR002776"],"award-info":[{"award-number":["DP2 TR002776"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["DP2 TR002776"],"award-info":[{"award-number":["DP2 TR002776"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Chem."],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41557-024-01557-2","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T06:11:11Z","timestamp":1720505471000},"page":"1687-1697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0011-5222","authenticated-orcid":false,"given":"Xuexiang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad-Gabriel","family":"Alameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9444-8505","authenticated-orcid":false,"given":"Ningqiang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5719-1336","authenticated-orcid":false,"given":"Lulu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9651-5014","authenticated-orcid":false,"given":"Majed","family":"Ghattas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goutham","family":"Bojja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-8111","authenticated-orcid":false,"given":"Junchao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-6036","authenticated-orcid":false,"given":"Gan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-2867","authenticated-orcid":false,"given":"Claude C.","family":"Warzecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3607-790X","authenticated-orcid":false,"given":"Marshall S.","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5855-233X","authenticated-orcid":false,"given":"Rakan","family":"El-Mayta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-8676","authenticated-orcid":false,"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5740-643X","authenticated-orcid":false,"given":"Andrew E.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9630-3131","authenticated-orcid":false,"given":"James M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1501-6510","authenticated-orcid":false,"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3628-2244","authenticated-orcid":false,"given":"Michael J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"1557_CR1","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/j.matt.2020.09.020","volume":"3","author":"X Han","year":"2020","unstructured":"Han, X., Mitchell, M. J. & Nie, G. Nanomaterials for therapeutic RNA delivery. Matter 3, 1948\u20131975 (2020).","journal-title":"Matter"},{"key":"1557_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1557_CR3","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1039\/D1CS00617G","volume":"51","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y. et al. Emerging mRNA technologies: delivery strategies and biomedical applications. Chem. Soc. Rev. 51, 3828\u20133845 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"1557_CR4","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1557_CR5","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/jbm.a.37356","volume":"110","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Rational design of anti-inflammatory lipid nanoparticles for mRNA delivery. J. Biomed. Mater. Res. A 110, 1101\u20131108 (2022).","journal-title":"J. Biomed. Mater. Res. A"},{"key":"1557_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27493-0","volume":"12","author":"X Han","year":"2021","unstructured":"Han, X. et al. An ionizable lipid toolbox for RNA delivery. Nat. Commun. 12, 7233 (2021).","journal-title":"Nat. Commun."},{"key":"1557_CR7","doi-asserted-by":"publisher","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","volume":"121","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y., Sun, C., Wang, C., Jankovic, K. E. & Dong, Y. Lipids and lipid derivatives for RNA delivery. Chem. Rev. 121, 12181\u201312277 (2021).","journal-title":"Chem. Rev."},{"key":"1557_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris, Y., Gupta, M., Kim, J. & Sahay, G. Chemistry of lipid nanoparticles for RNA delivery. Acc. Chem. Res. 55, 2\u201312 (2022).","journal-title":"Acc. Chem. Res."},{"key":"1557_CR9","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509\u20131519 (2018).","journal-title":"Mol. Ther."},{"key":"1557_CR10","doi-asserted-by":"publisher","first-page":"eabc2315","DOI":"10.1126\/sciadv.abc2315","volume":"6","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Sci. Adv. 6, eabc2315 (2020).","journal-title":"Sci. Adv."},{"key":"1557_CR11","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"1557_CR12","doi-asserted-by":"publisher","first-page":"2106727","DOI":"10.1002\/adfm.202106727","volume":"32","author":"M Cornebise","year":"2022","unstructured":"Cornebise, M. et al. Discovery of a novel amino lipid that improves lipid nanoparticle performance through specific interactions with mRNA. Adv. Funct. Mater. 32, 2106727 (2022).","journal-title":"Adv. Funct. Mater."},{"key":"1557_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201805097","volume":"15","author":"KA Hajj","year":"2019","unstructured":"Hajj, K. A. et al. Branched-tail lipid nanoparticles potently deliver mRNA in vivo due to enhanced ionization at endosomal pH. Small 15, e1805097 (2019).","journal-title":"Small"},{"key":"1557_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nbt1402","volume":"26","author":"A Akinc","year":"2008","unstructured":"Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561\u2013569 (2008).","journal-title":"Nat. Biotechnol."},{"key":"1557_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172\u2013176 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1557_CR16","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. 51, 8529\u20138533 (2012).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1557_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5277","volume":"5","author":"KA Whitehead","year":"2014","unstructured":"Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).","journal-title":"Nat. Commun."},{"key":"1557_CR18","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1073\/pnas.0910603106","volume":"107","author":"KT Love","year":"2010","unstructured":"Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864\u20131869 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1557_CR19","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","volume":"37","author":"L Miao","year":"2019","unstructured":"Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174\u20131185 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1557_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2217\/nnm.14.192","volume":"10","author":"S Altinoglu","year":"2015","unstructured":"Altinoglu, S., Wang, M. & Xu, Q. Combinatorial library strategies for synthesis of cationic lipid-like nanoparticles and their potential medical applications. Nanomedicine 10, 643\u2013657 (2015).","journal-title":"Nanomedicine"},{"key":"1557_CR21","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1039\/c3py00004d","volume":"4","author":"P Espeel","year":"2013","unstructured":"Espeel, P., Goethals, F., Driessen, F., Nguyen, L.-T. T. & Du Prez, F. E. One-pot, additive-free preparation of functionalized polyurethanes via amine-thiol-ene conjugation. Polym. Chem. 4, 2449\u20132456 (2013).","journal-title":"Polym. Chem."},{"key":"1557_CR22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1073\/pnas.1520756113","volume":"113","author":"K Zhou","year":"2016","unstructured":"Zhou, K. et al. Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model. Proc. Natl Acad. Sci. USA 113, 520\u2013525 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1557_CR23","doi-asserted-by":"publisher","first-page":"7326","DOI":"10.1039\/c3cs60065c","volume":"42","author":"JY Quek","year":"2013","unstructured":"Quek, J. Y., Davis, T. P. & Lowe, A. B. Amidine functionality as a stimulus-responsive building block. Chem. Soc. Rev. 42, 7326\u20137334 (2013).","journal-title":"Chem. Soc. Rev."},{"key":"1557_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","volume":"114","author":"H Lv","year":"2006","unstructured":"Lv, H., Zhang, S., Wang, B., Cui, S. & Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114, 100\u2013109 (2006).","journal-title":"J. Control. Release"},{"key":"1557_CR25","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1089\/10430340050207984","volume":"11","author":"JD Tousignant","year":"2000","unstructured":"Tousignant, J. D. et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum. Gene Ther. 11, 2493\u20132513 (2000).","journal-title":"Hum. Gene Ther."},{"key":"1557_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nbt.2612","volume":"31","author":"J Gilleron","year":"2013","unstructured":"Gilleron, J. et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638\u2013646 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1557_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14527-2","volume":"11","author":"S Patel","year":"2020","unstructured":"Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).","journal-title":"Nat. Commun."},{"key":"1557_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207486","volume":"34","author":"J Yan","year":"2022","unstructured":"Yan, J. et al. Nanomaterials-mediated co-stimulation of toll-like receptors and CD40 for antitumor immunity. Adv. Mater. 34, e2207486 (2022).","journal-title":"Adv. Mater."},{"key":"1557_CR29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nnano.2013.181","volume":"8","author":"S Tenzer","year":"2013","unstructured":"Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8, 772\u2013781 (2013).","journal-title":"Nat. Nanotechnol."},{"key":"1557_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2012.202","volume":"21","author":"C Pollard","year":"2013","unstructured":"Pollard, C. et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 21, 251\u2013259 (2013).","journal-title":"Mol. Ther."},{"key":"1557_CR31","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1038\/mt.2014.133","volume":"22","author":"LA Brito","year":"2014","unstructured":"Brito, L. A. et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 22, 2118\u20132129 (2014).","journal-title":"Mol. Ther."},{"key":"1557_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ymthe.2017.12.024","volume":"26","author":"MG Prieve","year":"2018","unstructured":"Prieve, M. G. et al. Targeted mRNA therapy for ornithine transcarbamylase deficiency. Mol. Ther. 26, 801\u2013813 (2018).","journal-title":"Mol. Ther."},{"key":"1557_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.omtn.2022.04.010","volume":"28","author":"S Bartesaghi","year":"2022","unstructured":"Bartesaghi, S. et al. Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance and hepatic steatosis in diet-induced obese mice. Mol. Ther. Nucleic Acids 28, 500\u2013513 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1557_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.tem.2014.03.001","volume":"25","author":"RE Gimeno","year":"2014","unstructured":"Gimeno, R. E. & Moller, D. E. FGF21-based pharmacotherapy\u2014potential utility for metabolic disorders. Trends Endocrinol. Metab. 25, 303\u2013311 (2014).","journal-title":"Trends Endocrinol. Metab."},{"key":"1557_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1021\/acs.accounts.1c00601","volume":"55","author":"D Loughrey","year":"2022","unstructured":"Loughrey, D. & Dahlman, J. E. Non-liver mRNA delivery. Acc. Chem. Res. 55, 13\u201323 (2022).","journal-title":"Acc. Chem. Res."},{"key":"1557_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1557_CR38","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396\u2013401 (2016).","journal-title":"Nature"},{"key":"1557_CR39","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","volume":"29","author":"I Tombacz","year":"2021","unstructured":"Tombacz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol. Ther. 29, 3293\u20133304 (2021).","journal-title":"Mol. Ther."},{"key":"1557_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41563-020-00886-0","volume":"20","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat. Mater. 20, 701\u2013710 (2021).","journal-title":"Nat. Mater."},{"key":"1557_CR42","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"1557_CR43","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn, J. D. et al. A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227\u20132235 (2018).","journal-title":"Cell Rep."},{"key":"1557_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersdorfer","year":"2019","unstructured":"Baiersdorfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1557_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41467-022-35637-z","volume":"14","author":"X Han","year":"2023","unstructured":"Han, X. et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nat. Commun. 14, 75 (2023).","journal-title":"Nat. Commun."},{"key":"1557_CR46","doi-asserted-by":"publisher","first-page":"eaba1028","DOI":"10.1126\/sciadv.aba1028","volume":"7","author":"RS Riley","year":"2021","unstructured":"Riley, R. S. et al. Ionizable lipid nanoparticles for in utero mRNA delivery. Sci. Adv. 7, eaba1028 (2021).","journal-title":"Sci. Adv."},{"key":"1557_CR47","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley, M. M. et al. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 20, 1578\u20131589 (2020).","journal-title":"Nano Lett."},{"key":"1557_CR48","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/jcc.540130714","volume":"13","author":"FA Momany","year":"1992","unstructured":"Momany, F. A. & Rone, R. Validation of the general purpose QUANTA\u00ae 3.2\/CHARMm\u00ae force field. J. Comput. Chem. 13, 888\u2013900 (1992).","journal-title":"J. Comput. Chem."},{"key":"1557_CR49","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1021\/jp8111556","volume":"113","author":"M Mantina","year":"2009","unstructured":"Mantina, M., Chamberlin, A. C., Valero, R., Cramer, C. J. & Truhlar, D. G. Consistent van der Waals radii for the whole main group. J. Phys. Chem. A 113, 5806\u20135812 (2009).","journal-title":"J. Phys. Chem. A"},{"key":"1557_CR50","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nbt.4182","volume":"36","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol. Nat. Biotechnol. 36, 717\u2013725 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1557_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","volume":"221","author":"A Frey","year":"1998","unstructured":"Frey, A., Di Canzio, J. & Zurakowski, D. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221, 35\u201341 (1998).","journal-title":"J. Immunol. Methods"}],"container-title":["Nature Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41557-024-01557-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41557-024-01557-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41557-024-01557-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T22:01:52Z","timestamp":1727906512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41557-024-01557-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1557"],"URL":"https:\/\/doi.org\/10.1038\/s41557-024-01557-2","relation":{},"ISSN":["1755-4330","1755-4349"],"issn-type":[{"value":"1755-4330","type":"print"},{"value":"1755-4349","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"26 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.H. and M.J.M. are inventors on a patent filed by the Trustees of the University of Pennsylvania (US provisional patent application no. 63\/589,051, filed 10 October 2023) describing the amidine-incorporated degradable lipid nanoparticle technology in this paper. In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that D.W. is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. M.J.M., X.H., D.W. and M.-G.A. are also named on patents describing the use of lipid nanoparticles, and lipid compositions for nucleic acid delivery and vaccination. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. J.M.W. is a paid advisor to and holds equity in iECURE, Passage Bio and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies. He has sponsored research agreements with Amicus Therapeutics, CBM, Ceva Sant\u00e9 Animale, Elaaj Bio, FA212, Foundation for Angelman Syndrome Therapeutics, former G2 Bio asset companies, iECURE and Passage Bio, which are licensees of Penn technology. J.M.W. and C.C.W. are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}